Inclusion Criteria:

- age > 18 years

- medulloblastoma (+/- postoperative residual tumor, M0) or medulloblastoma (+/-
postoperative residual tumor, M1-M3) respectively

- primary diagnosis of the tumor

- no previous chemo- or radiation therapy

- Karnofsky-Index ≥ 70%

- WBC ≥ 3000/μl; thrombocytes ≥ 100 000/μl; Hb ≥ 10 g/dl

- creatinine =< 1,5 ULN; Bilirubin =< 1,5 ULN; GPT, GOT, AP =< 2,5 ULN

- HIV and hepatitis B/C negative

- no factors / any medical condition affecting patient's compliance

- patient needs to fulfil protocol's requirements

- patient is willing to use highly effective methods of contraception during dosing and
for 6 months after the last dose; women of child-bearing potential must have a
negative hCG laboratory test at baseline; pregnancy tests must be repeated every 4
weeks

- patient's written consent

Exclusion Criteria:

- age < 18 years

- histologically not confirmed Medulloblastoma

- by chemo- or radiotherapy treated recidive tumor

- other cancer (with exception of surgically cured carcinoma in situ of the cervix and
non-melanocytic skin tumors)

- hypersensitivity or contraindication against one of the used drugs

- current or planned participation to another clinical trial during this study Any
other condition which, in the opinion of the Investigator, would make the patient
unsuitable for enrolment or could interfere with the patient participating in and
completing the study

- Any medical condition associated with high medical risk or contraindicated to use
chemotherapeutic agents as indicated in current product package insert

- Pregnant or nursing (lactating) women; women or men not willing to use a highly
effective methods of contraception